Nov 28, 2017 — 5 min read
Brandon B. Suh, Chief Medical Officer of Lunit answers the most frequently asked questions about Lunit INSIGHT.
Lunit INSIGHT is a new and advanced cloud-based artificial intelligence solution for real-time medical image analysis. During RSNA 2017, we will be live-demonstrating the software which was developed with our own cutting-edge deep learning technology. Lunit INSIGHT is currently available to the public at http://insight.lunit.io, free of charge.
Users can upload their medical images and receive AI analysis results in just a few seconds. The analysis results include not only the level of abnormality shown in terms of a “confidence score”, but also the visualization of the AI’s attention map. In addition, other functions commonly found in PACS viewers, such as contrast level adjustment, zoom in/out, etc, are all available as well so that users can take a good look at the images uploaded.
Lunit’s chest x-ray solution detects major chest abnormalities, lung nodule/mass, consolidation, and pneumothorax, with an unprecedented high level of accuracy 一 97% standalone accuracy in nodule detection, 99% for consolidation and pneumothorax. According to the National Lung Screening Trial (NLST), 26.5% of lung cancer was shown to be missed by chest x-ray. Noting the common use of chest x-ray throughout general medical practice with more than 1 billion chest x-ray exams performed every year worldwide, decreasing the proportion of missed cases even by 10% would translate into a significant clinical benefit.
What’s foremost significant is how our solutions have been proven to significantly increase the diagnostic performance of its users up to 20%, from non-radiology physicians to thoracic radiology experts. Such increase in performance level has been, interestingly, shown to be dependent on the level of trust a user has on the results of our solutions, especially for equivocal lesions or lesions that are hidden and difficult to be visualized by extrapulmonary structures, such as the clavicle, hilar structure, heart, or the diaphragm.
Other than the chest x-ray solution, Lunit’s mammography solution to detect suspicious breast cancer lesions is in its final stages of development. Lunit INSIGHT for Mammography is expected to be publically released by the first quarter of 2018. Lunit is also doing research in developing solutions for digital breast tomosynthesis, chest CT, and coronary CT angiography.
Lunit’s AIs are trained by a huge collection of de-identified clinical data from Lunit’s partner hospitals, 18 in a total number of partnerships. The total number of images that have been directly used in our research has reached over 1 million case images, of which around 200k are chest x-ray images and another 200k are mammography images. Moreover, most of the images collected are curated with proper ground truth labels including follow-up data, clinical data, as well as pathology data, which significantly help Lunit’s AI technology to be translated into high performing algorithms. Based on the given image data, the AI algorithms are then specifically trained to detect target diseases or radiologic findings, including lung cancer, tuberculosis, pneumonia, pneumothorax, and breast cancer for chest x-ray and mammograms, for example.
Proper clinical validation is an important part of presenting meaningful AI solutions that have a high clinical impact. We put a lot of efforts to conduct large-scale clinical studies, not just in Korea where Lunit is based, but also in the United States and elsewhere. Large-scale multi-center reader studies are set to be conducted in early 2018 with multiple leading hospitals in Korea and the US for Lunit’s chest x-ray and mammography solutions, for which publication of the results are targeted for late 2018. FDA approval for Lunit’s chest x-ray and mammography solutions are expected to be achieved by end of 2018.
We would like to connect with more people who are interested in integrating our solutions into their systems to get valuable feedback and promote our solutions. Testing our solutions for pre-market evaluation is an important endeavor for Lunit, because testing in actual routine clinical settings would be an important step to double-check for any unexpected problems and eventually earn the trust of end users, not only in terms of the accuracy of the solutions but also in terms of usability. While early adoption will be based on a small number of reference sites, we developed multiple ways that can make Lunit INSIGHT easily accommodated, including both cloud-based systems and library packaging systems that can be run locally without the need for images to leave the hospital premises.
The public release of Lunit INSIGHT is also expected to help us establish partnerships with vendors and platform companies that will eventually help distribute Lunit’s products, especially once the products are regulatory approved. We are hoping that after users witness the high level of our solutions themselves, it would drive the demand for adoption of our solutions in their affiliated institutions.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021